Details

Autor(en) / Beteiligte

• Vos, Robin, MD, PhD
• Ruttens, David, MD
• Verleden, Stijn E., MsC, PhD
• Vandermeulen, Elly, MsC, PhD
• Bellon, Hannelore, MsC
• Van Herck, Anke, MD
• Sacreas, Annelore, MsC
• Heiglu, Tobias, MsC
• Schaevers, Veronique, MsC
• Van Raemdonck, Dirk E., MD, PhD
• Verbeken, Eric K., MD, PhD
• Neyrinck, Arne P., MD, PhD
• Dupont, Lieven J., MD, PhD
• Yserbyt, Jonas, MD, PhD
• Vanaudenaerde, Bart M., MsC, PhD
• Verleden, Geert M., MD, PhD

Titel

High-dose vitamin D after lung transplantation: A randomized trial

Ist Teil von

• The Journal of heart and lung transplantation, 2017-08, Vol.36 (8), p.897-905

Ort / Verlag

United States: Elsevier Inc

Erscheinungsjahr

2017

Quelle

MEDLINE

Beschreibungen/Notizen

• Background Vitamin D may have innate immunomodulatory functions with potentially beneficial therapeutic effects in lung transplant recipients. Methods A single-center, double blind, randomized, placebo-controlled, prevention trial of once monthly oral vitamin D (cholecalciferol, 100,000 IU) (n=44) versus placebo (n=43) during 2 years in adult lung transplant recipients, enrolled from October 2010 to August 2013. Primary outcome was prevalence of chronic lung allograft dysfunction (CLAD) 3 years after transplantation. Secondary outcomes included overall survival, prevalence of acute rejection, lymphocytic bronchiolitis and infection, lung function, pulmonary and systemic inflammation; and bone mineral density. Results All included patients underwent bilateral lung transplantation and were mostly middle-aged males with prior smoking-related emphysema. 25(OH)D levels after 1 year (p<0.001) and 2 years (p<0.001) were significantly higher in vitamin D compared to placebo. No difference was observed for CLAD prevalence (p=0.7) or CLAD-free survival between both groups (p=0.7). Secondary outcomes were overall comparable between both groups (all p>0.05). Conclusions Once monthly oral vitamin D supplementation after lung transplantation fails to demonstrate a significant difference in CLAD prevalence, nor in innate immunomodulatory or beneficial clinical effects compared to placebo. Clinicaltrial.gov identifier: NTC01212406